Trials / Completed
CompletedNCT02932969
Study With Healthy Japanese and Non-Asian Participants With BMS-986231
A Randomized, Double-Blind, Placebo-controlled, Single Continuous Intravenous Infusion Study of BMS-986231 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Japanese and Non- Asian Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this Phase 1 study is to evaluate the safety, tolerability, PK, and pharmacodynamics (PD) of BMS-986231 in healthy Japanese and Non-Asian participants. There is no formal hypothesis to be statistically tested.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986231 | |
| DRUG | BMS-986231 Placebo |
Timeline
- Start date
- 2016-10-04
- Primary completion
- 2017-05-26
- Completion
- 2017-05-26
- First posted
- 2016-10-13
- Last updated
- 2017-05-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02932969. Inclusion in this directory is not an endorsement.